Derek Archila

Gavin Clark-Gartner

Rajan Sharma

Samantha Semenkow

Tazeen Ahmad

Victor Floch

Yaron Werber

Alexander Thompson

Andy Chen

Douglas Tsao

James Gordon

Joel Beatty

Suzanne van Voorthuizen

Vikram Purohit

Yatin Suneja

Akash Tewari

Amy Li

Leland Gershell

Manos Mastorakis

Matthew Phipps

Myles Minter

Xian Deng

Alex Thompson

Brian Conley

Charles Pitman

Charles Pitman-King

Danielle Brill

David Nierengarten

Maddalena Delma Caiati

Mehdi Goudarzi

Nathanael Charoensook

Sean Laaman

Thomas J. Smith

Thomas Smith

- **argenx SE** announced **positive topline results** from the pivotal **ADAPT SERON study** of **VYVGART** in patients with AChR-Ab seronegative generalized myasthenia gravis (gMG) on **August 25, 2025**.  **[1697862_0001104659-25-082118_tm2524211d1_ex99-1.htm:0]** **[1697862_0001104659-25-082118_tm2524211d1_ex99-1.htm:1]** 
- The study **met its primary endpoint** (p-value=**0.0068**), demonstrating a statistically significant and clinically meaningful improvement in MG-ADL total score compared to placebo.  **[1697862_0001104659-25-082118_tm2524211d1_ex99-1.htm:1]** 
- This marks the **first global Phase 3 study** to show clinically meaningful improvements in disease activity across all three seronegative gMG subtypes: MuSK+, LRP4+, and triple seronegative.  **[1697862_0001104659-25-082118_tm2524211d1_ex99-1.htm:1]** 
- Based on these results, argenx plans to submit a **Supplemental Biologics License Application (sBLA)** to the U.S. Food and Drug Administration (FDA) by the **end of 2025** to expand the VYVGART label.  **[1697862_0001104659-25-082118_tm2524211d1_ex99-1.htm:1]**

argenx Reports Positive Topline Results for VYVGART ADAPT SERON Study

ARGENX (ARGX)